Navigation Links
Encision Reports Profitable Third Fiscal Quarter Results
Date:1/28/2010

BOULDER, Colo., Jan. 28 /PRNewswire-FirstCall/ -- Encision Inc. (OTC Bulletin Board: ECIA), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, reported its financial results for its third quarter of fiscal year 2010.

Net sales for the three months ended December 31, 2009 and December 31, 2008 totaled $3.3 million. The Company recorded net income of $149 thousand, or $.02 per share, for the third quarter of fiscal year 2010, compared to a net income of $233 thousand, or $.04 per share, for the third quarter of fiscal year 2009. Gross profit margin for the third quarter of fiscal year 2010 was 61.6%, as compared to 63.6% for the third quarter of fiscal year 2009. The lower gross profit margin for the third quarter of fiscal year 2010 was due to increased sales of lower gross profit margin products.

Net sales for the first nine months ended December 31, 2009 totaled $9.65 million, representing a 1% decrease over net sales of $9.71 million for the prior fiscal year's first nine months. The Company recorded net income of $359 thousand, or $.06 per share, for the first nine months of fiscal year 2010, compared to net income of $144 thousand, or $.02 per share, for the first nine months of fiscal year 2009. Gross profit margin for the first nine months of fiscal year 2010 and fiscal year 2009 was 62%.

Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM® Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's filings with the Securities and Exchange Commission. The Company does not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT:  Marcia McHaffie, Encision Inc., 303-444-2600, mmchaffie@encision.com

    
    
    
                                    Encision Inc.
                               Condensed Balance Sheets
                                (Amounts in thousands)
    
                                                 December 31,      March 31,
                                                    2009             2009
                                                 (Unaudited)       (Audited)
                                                 -----------       ----------
    ASSETS                                             
    Cash and cash equivalents                         $47              $85 
    Accounts receivable, net                        1,196            1,264 
    Inventories, net                                2,351            2,505 
    Prepaid expenses                                   92               36 
                                                 -----------       ----------
      Total current assets                          3,686            3,890 
                                                 -----------       ----------
    Equipment, net                                  1,095              840 
    Patents, net                                      265              216 
    Other assets                                       27               24 
                                                 -----------       ----------
      Total assets                                 $5,073           $4,970 
                                                 -----------       ----------
    LIABILITIES AND SHAREHOLDERS' EQUITY               
    Accounts payable                                 $373             $745 
    Accrued compensation                              337              406 
    Other accrued liabilities                         388              367 
    Line of credit                                     --              191 
                                                 -----------       ----------
      Total current liabilities                     1,098            1,709 
                                                 -----------       ----------
    Line of credit                                    275               -- 
                                                 -----------       ----------
    Common stock and additional paid-in capital    19,640           19,560 
    Accumulated (deficit)                         (15,940)         (16,299)
                                                 -----------       ----------
      Total shareholders' equity                    3,700            3,261 
                                                 -----------       ----------
      Total liabilities and shareholders' equity   $5,073           $4,970 
                                                 -----------       ----------
    
    
    
                                   Encision Inc.
                         Condensed Statements of Operations
                (Amounts in thousands, except per share information)
    
                                       (Unaudited)            (Unaudited)
                                   Three Months Ended      Nine Months Ended
                                   -------------------    -------------------
                                   December    December   December   December
                                      31,         31,        31,        31,
                                     2009        2008       2009       2008
                                   --------    --------   --------   --------
    Net sales                       $3,260      $3,271    $9,650     $9,711 
    Cost of sales                    1,251       1,192     3,664      3,715
                                   --------    --------   --------   --------
    Gross profit                     2,009       2,079     5,986      5,996 
                                   --------    --------   --------   --------
    Operating expenses:                       
      Sales and marketing            1,146       1,191     3,580      3,887 
      General and administrative       362         355     1,059      1,080 
      Research and development         341         286       947        856 
                                   --------    --------   --------   --------
        Total operating expenses     1,849       1,832     5,586      5,823 
                                   --------    --------   --------   --------
    Operating income                   160         247       400        173 
    Interest and other income 
     (expense), net                    (11)        (14)      (42)       (29)
                                   --------    --------   --------   --------
    Income before provision for 
     income taxes                      149         233       359        144 
    Provision for income taxes          ––          ––        ––         –– 
                                   --------    --------   --------   --------
    Net income                        $149        $233      $359       $144 
                                   ========    ========   ========   ========
    Net income per share-basic       $0.02       $0.04     $0.06      $0.02 
                                   ========    ========   ========   ========
    Net income per share-diluted     $0.02       $0.04     $0.06      $0.02 
                                   ========    ========   ========   ========
    Basic weighted average number        
     of shares                       6,455       6,455     6,455      6,453 
    Diluted weighted average number        
     of shares                       6,461       6,455     6,463      6,453 
    

SOURCE Encision Inc.

RELATED LINKS
http://www.encision.com

'/>"/>

SOURCE Encision Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Zimmer Reports Fourth Quarter and 2009 Financial Results
2. Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results
3. Lilly Reports Fourth-Quarter and Full-Year 2009 Results
4. P&G Reports Accelerated Sales and Unit Volume Growth
5. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
6. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
7. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010
8. Helix BioPharma Reports On 2009 Annual General Meeting
9. Solos Endoscopy, Inc. Reports Sales Increase for October 2009 and November 2009 as Compared to Same Two Months in 2008
10. Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase
11. Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , April 26, 2017 Phoenix Marketing Solutions ... fifteenth year of fulfilling its mission of transforming science into ... highly scrutinized, Phoenix,s innovative approach supports ... community about the latest advances in science and medicine — ... was founded in 2002 by Tracy Doyle ...
(Date:4/24/2017)... England , April 24, 2017 ... development, today announced the addition of a major ... ,Validated In-situ Plate Seeding,). The VIPS has been ... and 384 well microplates as part of the ... system offers a simple and more reliable solution ...
(Date:4/20/2017)...  Vivify Health, the pioneer and market leader of ... very significant patent for the advancement of healthcare delivery ... digital health.  This landmark patent provides the company with ... Vivify,s position as the leader in remote care.  ... company to apply consumer mobile devices, wireless biometrics, EMR ...
Breaking Medicine Technology:
(Date:4/28/2017)... Washington, DC (PRWEB) , ... April 28, 2017 ... ... Unplanned Pregnancy (The National Campaign) announces its support for the Access to ... by Sen. Jeanne Shaheen (D-NH) and Rep. Jackie Speier (D-CA), will help to ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create and edit ... the reporting process and provides a familiar interface that does not require additional ...
(Date:4/28/2017)... ... April 28, 2017 , ... Getting enough sleep affects much more than energy – ... just 19 hours without sleep can compromise motor reaction time, which can increase the risk ... Insurance is sharing the following tips from the NSF to help you sleep better and ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces the ... instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ... hour rated lamps utilize the existing electronic ballast, saving labor and maintenance costs. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children ... to more adverse experiences than children in the general population. That’s because foster ... neglect or other family challenges. While no fault of their own, youth who ...
Breaking Medicine News(10 mins):